Abstract
Aim:In cancer immunotherapy, biomarkers are important for identification of responsive patients. This study was aimed to find biomarkers that predict clinical outcome of WT1 peptide vaccination.Materials & methods:Candidate genes that were expressed differentially between long- and short-term survivors were identified by cDNA microarray analysis of peripheral blood mononuclear cells that were extracted from 30 glioblastoma patients (discovery set) prior to vaccination and validated by quantitative RT-PCR using discovery set and different 23 patients (validation set).Results: SDC-4 mRNA expression levels distinguished between the long- and short-term survivors: 1-year survival rates were 64.0 and 18.5% in SDC4-low and -high patients, respectively.Conclusion: SDC-4 is a novel predictive biomarker for the efficacy of WT1 peptide vaccine.
Highlights
In order to improve the clinical usefulness of WT1 peptide vaccine, it is important to enhance clinical efficacy and to select the responders to WT1 peptide vaccine
Peripheral blood mononuclear cells from 30 Glioblastoma multiforme (GBM) patients prior to WT1 vaccination in a discovery set were subjected to cDNA microarray analysis, candidate genes that differentially expressed between long- and short-term survivors were selected, followed by verification with quantitative RT-PCR
The filtrated candidate genes were validated for the correlation between gene expression levels and clinical effects using different 23 GBM patients of a validation set
Summary
Biomarkers are important for identification of responsive patients. This study was aimed to find biomarkers that predict clinical outcome of WT1 peptide vaccination.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
